Loading...
Reach Banner
Keywords
Last name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Felix Ratjen and Hartmut Grasemann.

 
Connection Strength
 
 
 
16.414
 
  1. Grasemann H, Klingel M, Avolio J, Prentice C, Gonska T, Tullis E, Ratjen F. Long-term effect of CFTR modulator therapy on airway nitric oxide. Eur Respir J. 2020 01; 55(1).
    View in: PubMed
    Score: 0.912
  2. Ratjen F, Waters V, Klingel M, McDonald N, Dell S, Leahy TR, Yau Y, Grasemann H. Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J. 2016 Mar; 47(3):829-36.
    View in: PubMed
    Score: 0.685
  3. Grasemann H, Gonska T, Avolio J, Klingel M, Tullis E, Ratjen F. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis. J Cyst Fibros. 2015 Nov; 14(6):727-32.
    View in: PubMed
    Score: 0.668
  4. Grasemann H, Jaecklin T, Mehl A, Huang H, Rafii M, Pencharz P, Ratjen F. Multitracer stable isotope quantification of arginase and nitric oxide synthase activity in a mouse model of pseudomonas lung infection. Mediators Inflamm. 2014; 2014:323526.
    View in: PubMed
    Score: 0.627
  5. Grasemann H, Ratjen F. Early lung disease in cystic fibrosis. Lancet Respir Med. 2013 Apr; 1(2):148-57.
    View in: PubMed
    Score: 0.568
  6. Grasemann H, Tullis E, Ratjen F. A randomized controlled trial of inhaled L-arginine in patients with cystic fibrosis. J Cyst Fibros. 2013 Sep; 12(5):468-74.
    View in: PubMed
    Score: 0.562
  7. Grasemann H, Shehnaz D, Enomoto M, Leadley M, Belik J, Ratjen F. L-ornithine derived polyamines in cystic fibrosis airways. PLoS One. 2012; 7(10):e46618.
    View in: PubMed
    Score: 0.551
  8. Ratjen F, Grasemann H. New therapies in cystic fibrosis. Curr Pharm Des. 2012; 18(5):614-27.
    View in: PubMed
    Score: 0.523
  9. Grasemann H, Ratjen F. Nitric oxide and L-arginine deficiency in cystic fibrosis. Curr Pharm Des. 2012; 18(5):726-36.
    View in: PubMed
    Score: 0.523
  10. Grasemann H, Al-Saleh S, Scott JA, Shehnaz D, Mehl A, Amin R, Rafii M, Pencharz P, Belik J, Ratjen F. Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with cystic fibrosis. Am J Respir Crit Care Med. 2011 May 15; 183(10):1363-8.
    View in: PubMed
    Score: 0.491
  11. Grasemann H, Ratjen F. Emerging therapies for cystic fibrosis lung disease. Expert Opin Emerg Drugs. 2010 Dec; 15(4):653-9.
    View in: PubMed
    Score: 0.477
  12. Grasemann H, Ratjen F. Editorial: leukocyte trafficking and matrix metalloproteinase-8 in obliterative bronchiolitis. J Leukoc Biol. 2010 Jan; 87(1):23-4.
    View in: PubMed
    Score: 0.455
  13. Grasemann H, Tschiedel E, Groch M, Klepper J, Ratjen F. Exhaled nitric oxide in children after accidental exposure to chlorine gas. Inhal Toxicol. 2007 Aug; 19(10):895-8.
    View in: PubMed
    Score: 0.385
  14. Grasemann H, Stehling F, Brunar H, Widmann R, Laliberte TW, Molina L, Döring G, Ratjen F. Inhalation of Moli1901 in patients with cystic fibrosis. Chest. 2007 May; 131(5):1461-6.
    View in: PubMed
    Score: 0.378
  15. Grasemann H, Schwiertz R, Grasemann C, Vester U, Racké K, Ratjen F. Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis. Respir Res. 2006 Jun 09; 7:87.
    View in: PubMed
    Score: 0.356
  16. Grasemann H, Kurtz F, Ratjen F. Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med. 2006 Jul 15; 174(2):208-12.
    View in: PubMed
    Score: 0.352
  17. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2006 Feb; 57(2):306-11.
    View in: PubMed
    Score: 0.345
  18. Grasemann H, Schwiertz R, Matthiesen S, Racké K, Ratjen F. Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med. 2005 Dec 15; 172(12):1523-8.
    View in: PubMed
    Score: 0.338
  19. Grasemann H, Grasemann C, Kurtz F, Tietze-Schillings G, Vester U, Ratjen F. Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur Respir J. 2005 Jan; 25(1):62-8.
    View in: PubMed
    Score: 0.322
  20. Grasemann H, Ratjen F. Gender-specific disease modification by NOS3. Br J Haematol. 2004 Jul; 126(1):160; author reply 161.
    View in: PubMed
    Score: 0.311
  21. Grasemann H, Storm van's Gravesande K, Buscher R, Drazen JM, Ratjen F. Effects of sex and of gene variants in constitutive nitric oxide synthases on exhaled nitric oxide. Am J Respir Crit Care Med. 2003 Apr 15; 167(8):1113-6.
    View in: PubMed
    Score: 0.281
  22. Grasemann H, Storm van's Gravesande K, Buscher R, Knauer N, Silverman ES, Palmer LJ, Drazen JM, Ratjen F. Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med. 2003 Feb 01; 167(3):390-4.
    View in: PubMed
    Score: 0.273
  23. Grasemann H, Ratjen F. [Pulmonary metabolism of nitric oxide (NO) in patients with cystic fibrosis]. Pneumologie. 2002 Jun; 56(6):376-81.
    View in: PubMed
    Score: 0.269
  24. Grasemann H, Storm van's Gravesande K, Gärtig S, Kirsch M, Büscher R, Drazen JM, Ratjen F. Nasal nitric oxide levels in cystic fibrosis patients are associated with a neuronal NO synthase (NOS1) gene polymorphism. Nitric Oxide. 2002 Mar; 6(2):236-41.
    View in: PubMed
    Score: 0.265
  25. Grasemann H, Ratjen F. Different subgroups of difficult asthma in children. Thorax. 2001 Nov; 56(11):895.
    View in: PubMed
    Score: 0.259
  26. Perrem L, Stanojevic S, Shaw M, Jensen R, McDonald N, Isaac SM, Davis M, Clem C, Guido J, Jara S, France L, Solomon M, Grasemann H, Waters V, Sweezey N, Sanders DB, Davis SD, Ratjen F. Lung Clearance Index to Track Acute Respiratory Events in School-Age Children with Cystic Fibrosis. Am J Respir Crit Care Med. 2021 Apr 15; 203(8):977-986.
    View in: PubMed
    Score: 0.249
  27. Pollak M, Shaw M, Wilson D, Solomon M, Ratjen F, Grasemann H. Bronchodilator responsiveness in cystic fibrosis children treated for pulmonary exacerbations. Pediatr Pulmonol. 2021 Apr 08.
    View in: PubMed
    Score: 0.249
  28. Stanojevic S, Davis SD, Perrem L, Shaw M, Retsch-Bogart G, Davis M, Jensen R, Clem CC, Isaac SM, Guido J, Jara S, France L, McDonald N, Solomon M, Sweezey N, Grasemann H, Waters V, Sanders DB, Ratjen FA. Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis. Eur Respir J. 2021 Feb 04.
    View in: PubMed
    Score: 0.246
  29. Grasemann H, Knauer N, Büscher R, Hübner K, Drazen JM, Ratjen F. Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. Am J Respir Crit Care Med. 2000 Dec; 162(6):2172-6.
    View in: PubMed
    Score: 0.243
  30. Ratjen F, Kavuk I, Gärtig S, Wiesemann HG, Grasemann H. Airway nitric oxide in infants with acute wheezy bronchitis. Pediatr Allergy Immunol. 2000 Nov; 11(4):230-5.
    View in: PubMed
    Score: 0.241
  31. Pollak M, Shaw M, Wilson D, Grasemann H, Ratjen F. Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis. Eur Respir J. 2020 08; 56(2).
    View in: PubMed
    Score: 0.238
  32. Grasemann H, Gaston B, Fang K, Paul K, Ratjen F. Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function. J Pediatr. 1999 Dec; 135(6):770-2.
    View in: PubMed
    Score: 0.226
  33. Grasemann H, Ratjen F. Cystic fibrosis lung disease: the role of nitric oxide. Pediatr Pulmonol. 1999 Dec; 28(6):442-8.
    View in: PubMed
    Score: 0.226
  34. Ratjen F, Gärtig S, Wiesemann HG, Grasemann H. Effect of inhaled nitric oxide on pulmonary function in cystic fibrosis. Respir Med. 1999 Aug; 93(8):579-83.
    View in: PubMed
    Score: 0.221
  35. Grasemann H, Gärtig SS, Wiesemann HG, Teschler H, Konietzko N, Ratjen F. Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome. Eur Respir J. 1999 Jan; 13(1):114-8.
    View in: PubMed
    Score: 0.212
  36. Ratjen F, Klingel M, Black P, Powers MR, Grasemann H, Solomon M, Sagel SD, Donaldson SH, Rowe SM, Rosenfeld M. Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial. Am J Respir Crit Care Med. 2018 08 15; 198(4):526-528.
    View in: PubMed
    Score: 0.207
  37. Grasemann H, Ioannidis I, Tomkiewicz RP, de Groot H, Rubin BK, Ratjen F. Nitric oxide metabolites in cystic fibrosis lung disease. Arch Dis Child. 1998 Jan; 78(1):49-53.
    View in: PubMed
    Score: 0.198
  38. Grasemann H, Michler E, Wallot M, Ratjen F. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol. 1997 Sep; 24(3):173-7.
    View in: PubMed
    Score: 0.194
  39. Grasemann H, Ciet P, Amin R, McDonald N, Klingel M, Tiddens HAWM, Ratjen F, Grosse-Wortmann L. Changes in magnetic resonance imaging scores and ventilation inhomogeneity in children with cystic fibrosis pulmonary exacerbations. Eur Respir J. 2017 08; 50(2).
    View in: PubMed
    Score: 0.193
  40. Grasemann H, Ioannidis I, de Groot H, Ratjen F. Metabolites of nitric oxide in the lower respiratory tract of children. Eur J Pediatr. 1997 Jul; 156(7):575-8.
    View in: PubMed
    Score: 0.191
  41. Grasemann H, Wiesemann HG, Ratjen F. [The importance of lung function as a predictor of 2-year mortality in mucoviscidosis]. Pneumologie. 1995 Aug; 49(8):466-9.
    View in: PubMed
    Score: 0.168
  42. Waters VJ, Stanojevic S, Sonneveld N, Klingel M, Grasemann H, Yau YC, Tullis E, Wilcox P, Freitag A, Chilvers M, Ratjen FA. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. J Cyst Fibros. 2015 Nov; 14(6):755-62.
    View in: PubMed
    Score: 0.162
  43. Jaecklin T, Duerr J, Huang H, Rafii M, Bear CE, Ratjen F, Pencharz P, Kavanagh BP, Mall MA, Grasemann H. Lung arginase expression and activity is increased in cystic fibrosis mouse models. J Appl Physiol (1985). 2014 Aug 01; 117(3):284-8.
    View in: PubMed
    Score: 0.155
  44. Mehl A, Ghorbani P, Douda D, Huang H, Palaniyar N, Ratjen F, Grasemann H. Effect of arginase inhibition on pulmonary L-arginine metabolism in murine Pseudomonas pneumonia. PLoS One. 2014; 9(3):e90232.
    View in: PubMed
    Score: 0.152
  45. Grasemann H, Ratjen F, Solomon M. Aquagenic wrinkling of the palms in a patient with cystic fibrosis. N Engl J Med. 2013 Dec 12; 369(24):2362-3.
    View in: PubMed
    Score: 0.150
  46. Amin R, Charron M, Grinblat L, Shammas A, Grasemann H, Graniel K, Ciet P, Tiddens H, Ratjen F. Cystic fibrosis: detecting changes in airway inflammation with FDG PET/CT. Radiology. 2012 Sep; 264(3):868-75.
    View in: PubMed
    Score: 0.136
  47. Al-Saleh S, Dell SD, Grasemann H, Yau YC, Waters V, Martin S, Ratjen F. Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr. 2010 Dec; 157(6):1006-1011.e1.
    View in: PubMed
    Score: 0.118
  48. Grasemann C, Ratjen F, Schnabel D, Reutershahn E, Vester U, Grasemann H. Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. Eur Respir J. 2008 Apr; 31(4):815-21.
    View in: PubMed
    Score: 0.099
  49. Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Döring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol. 2007 Mar; 42(3):249-55.
    View in: PubMed
    Score: 0.094
  50. Stehling F, Roll C, Ratjen F, Grasemann H. Nasal nitric oxide to diagnose primary ciliary dyskinesia in newborns. Arch Dis Child Fetal Neonatal Ed. 2006 May; 91(3):F233.
    View in: PubMed
    Score: 0.088
  51. Tschiedel E, Grasemann H, Ratjen F. Mycobacterium chelonae in a CF patient with anaplastic large cell lymphoma. J Cyst Fibros. 2006 May; 5(2):133-6.
    View in: PubMed
    Score: 0.086
  52. Knauer N, Ratjen F, Grasemann H. [Cystic fibrosis modifying genes]. Pneumologie. 2005 Jun; 59(6):395-404.
    View in: PubMed
    Score: 0.083
  53. Straub V, Ratjen F, Amthor H, Voit T, Grasemann H. Airway nitric oxide in Duchenne muscular dystrophy. J Pediatr. 2002 Jul; 141(1):132-4.
    View in: PubMed
    Score: 0.068
  54. Büscher R, Eilmes KJ, Grasemann H, Torres B, Knauer N, Sroka K, Insel PA, Ratjen F. beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics. 2002 Jul; 12(5):347-53.
    View in: PubMed
    Score: 0.068
  55. Ratjen F, Grasemann H, Wolstein R, Wiesemann HG. Isovolume pressure/flow curves of rapid thoracoabdominal compressions in infants without respiratory disease. Pediatr Pulmonol. 1998 Sep; 26(3):197-203.
    View in: PubMed
    Score: 0.052
  56. Yau YC, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M, Grasemann H, Zlosnik J, Speert D, Corey M, Stanojevic S, Matukas L, Leahy TR, Shih S, Waters V. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J Cyst Fibros. 2015 Mar; 14(2):262-6.
    View in: PubMed
    Score: 0.040
  57. Corvol H, Beucher J, Boëlle PY, Busson PF, Muselet-Charlier C, Clement A, Ratjen F, Grasemann H, Laki J, Palmer CN, Elborn JS, Mehta A. Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. J Cyst Fibros. 2012 Jan; 11(1):63-7.
    View in: PubMed
    Score: 0.032
  58. Mateos-Corral D, Coombs R, Grasemann H, Ratjen F, Dell SD. Diagnostic value of nasal nitric oxide measured with non-velum closure techniques for children with primary ciliary dyskinesia. J Pediatr. 2011 Sep; 159(3):420-4.
    View in: PubMed
    Score: 0.031
  59. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, Pavord ID, Ratjen F, Silkoff PE, Taylor DR, Zamel N. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest. 2010 Sep; 138(3):682-92.
    View in: PubMed
    Score: 0.030
  60. Corvol H, Boelle PY, Brouard J, Knauer N, Chadelat K, Henrion-Caude A, Flamant C, Muselet-Charlier C, Boule M, Fauroux B, Vallet C, Feingold J, Ratjen F, Grasemann H, Clement A. Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatr Pulmonol. 2008 Dec; 43(12):1224-32.
    View in: PubMed
    Score: 0.026
  61. Büscher R, Hoerning A, Patel HH, Zhang S, Arthur DB, Grasemann H, Ratjen F, Insel PA. P2Y2 receptor polymorphisms and haplotypes in cystic fibrosis and their impact on Ca2+ influx. Pharmacogenet Genomics. 2006 Mar; 16(3):199-205.
    View in: PubMed
    Score: 0.022
  62. Tang CM, Hoerning A, Büscher R, O'Connor DT, Ratjen F, Grasemann H, Insel PA. Human adenosine 2B receptor: SNP discovery and evaluation of expression in patients with cystic fibrosis. Pharmacogenet Genomics. 2005 May; 15(5):321-7.
    View in: PubMed
    Score: 0.021
  63. Brouard J, Knauer N, Boelle PY, Corvol H, Henrion-Caude A, Flamant C, Bremont F, Delaisi B, Duhamel JF, Marguet C, Roussey M, Miesch MC, Chadelat K, Boule M, Fauroux B, Ratjen F, Grasemann H, Clement A. Influence of interleukin-10 on Aspergillus fumigatus infection in patients with cystic fibrosis. J Infect Dis. 2005 Jun 01; 191(11):1988-91.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.